Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond
For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with miss...
Ausführliche Beschreibung
Autor*in: |
Ursula Vogl [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2021 |
---|
Übergeordnetes Werk: |
In: healthbook TIMES. Oncology Hematology - THE HEALTHBOOK COMPANY LTD., 2022, 9(2021), 3 |
---|---|
Übergeordnetes Werk: |
volume:9 ; year:2021 ; number:3 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.36000/hbT.OH.2021.09.046 |
---|
Katalog-ID: |
DOAJ08663187X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ08663187X | ||
003 | DE-627 | ||
005 | 20240413120804.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230311s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.36000/hbT.OH.2021.09.046 |2 doi | |
035 | |a (DE-627)DOAJ08663187X | ||
035 | |a (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a Ursula Vogl |e verfasserin |4 aut | |
245 | 1 | 0 | |a Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. | ||
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
773 | 0 | 8 | |i In |t healthbook TIMES. Oncology Hematology |d THE HEALTHBOOK COMPANY LTD., 2022 |g 9(2021), 3 |w (DE-627)1786544288 |w (DE-600)3106733-5 |x 26732106 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2021 |g number:3 |
856 | 4 | 0 | |u https://doi.org/10.36000/hbT.OH.2021.09.046 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.36000/hbT.OH.2021.09.046 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2673-2092 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2673-2106 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 9 |j 2021 |e 3 |
author_variant |
u v uv |
---|---|
matchkey_str |
article:26732106:2021----::rteilacnmotmlramnotosn |
hierarchy_sort_str |
2021 |
publishDate |
2021 |
allfields |
10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3 |
spelling |
10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3 |
allfields_unstemmed |
10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3 |
allfieldsGer |
10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3 |
allfieldsSound |
10.36000/hbT.OH.2021.09.046 doi (DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 DE-627 ger DE-627 rakwb eng Ursula Vogl verfasserin aut Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. Medicine R In healthbook TIMES. Oncology Hematology THE HEALTHBOOK COMPANY LTD., 2022 9(2021), 3 (DE-627)1786544288 (DE-600)3106733-5 26732106 nnns volume:9 year:2021 number:3 https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 kostenfrei https://doi.org/10.36000/hbT.OH.2021.09.046 kostenfrei https://doaj.org/toc/2673-2092 Journal toc kostenfrei https://doaj.org/toc/2673-2106 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 3 |
language |
English |
source |
In healthbook TIMES. Oncology Hematology 9(2021), 3 volume:9 year:2021 number:3 |
sourceStr |
In healthbook TIMES. Oncology Hematology 9(2021), 3 volume:9 year:2021 number:3 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Medicine R |
isfreeaccess_bool |
true |
container_title |
healthbook TIMES. Oncology Hematology |
authorswithroles_txt_mv |
Ursula Vogl @@aut@@ |
publishDateDaySort_date |
2021-01-01T00:00:00Z |
hierarchy_top_id |
1786544288 |
id |
DOAJ08663187X |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ08663187X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413120804.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.36000/hbT.OH.2021.09.046</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ08663187X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ursula Vogl</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">healthbook TIMES. Oncology Hematology</subfield><subfield code="d">THE HEALTHBOOK COMPANY LTD., 2022</subfield><subfield code="g">9(2021), 3</subfield><subfield code="w">(DE-627)1786544288</subfield><subfield code="w">(DE-600)3106733-5</subfield><subfield code="x">26732106</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36000/hbT.OH.2021.09.046</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36000/hbT.OH.2021.09.046</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2092</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2106</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield></datafield></record></collection>
|
author |
Ursula Vogl |
spellingShingle |
Ursula Vogl misc Medicine misc R Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond |
authorStr |
Ursula Vogl |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1786544288 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut |
collection |
DOAJ |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
26732106 |
topic_title |
Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond |
topic |
misc Medicine misc R |
topic_unstemmed |
misc Medicine misc R |
topic_browse |
misc Medicine misc R |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
healthbook TIMES. Oncology Hematology |
hierarchy_parent_id |
1786544288 |
hierarchy_top_title |
healthbook TIMES. Oncology Hematology |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1786544288 (DE-600)3106733-5 |
title |
Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond |
ctrlnum |
(DE-627)DOAJ08663187X (DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6 |
title_full |
Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond |
author_sort |
Ursula Vogl |
journal |
healthbook TIMES. Oncology Hematology |
journalStr |
healthbook TIMES. Oncology Hematology |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2021 |
contenttype_str_mv |
txt |
author_browse |
Ursula Vogl |
container_volume |
9 |
format_se |
Elektronische Aufsätze |
author-letter |
Ursula Vogl |
doi_str_mv |
10.36000/hbT.OH.2021.09.046 |
title_sort |
urothelial carcinoma: optimal treatment options in first-line and beyond |
title_auth |
Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond |
abstract |
For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. |
abstractGer |
For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. |
abstract_unstemmed |
For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond |
url |
https://doi.org/10.36000/hbT.OH.2021.09.046 https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6 https://doaj.org/toc/2673-2092 https://doaj.org/toc/2673-2106 |
remote_bool |
true |
ppnlink |
1786544288 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.36000/hbT.OH.2021.09.046 |
up_date |
2024-07-03T21:51:19.316Z |
_version_ |
1803596311371448321 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ08663187X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413120804.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.36000/hbT.OH.2021.09.046</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ08663187X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9e6d4a962e86486cae74a17616a331b6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ursula Vogl</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urothelial Carcinoma: Optimal Treatment Options in First-Line and Beyond</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">For many years, the standard treatment approach in first-line for advanced urothelial carcinoma (UC) was platinum-based chemotherapy, with the choice of agent dependent on cisplatin-eligibility and relatively limited second-line therapy options included taxanes or vinflunine, thus although with missing approval in Switzerland.^1^ In the last years, the treatment landscape has changed due to the emergence of new targeted approaches, including immune checkpoint inhibitors (ICIs).^2^ In Switzerland, programmed death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors including pembrolizumab, atezolizumab and nivolumab are currently approved for the treatment of locally advanced or metastatic UC in adults having progressed on platinum-based chemotherapy,^3–5^ as well as pembrolizumab and atezolizumab in PD-L1 positive treatment naïve patients if platinum unfit. Evidence from a recent phase III trial has led to a new standard of care with a switch maintenance approach with the PD-L1 inhibitor avelumab for UC patients who are progression-free following platinum-based chemotherapy. Several novel emerging targeted therapies such as antibody-drug conjugates (ADC) or fibroblast growth factor receptor (FGFR) inhibitors are also being investigated in treatment-naïve as well as pretreated, platinum-and checkpoint inhibitor refractory patients with locally advanced or metastatic UC. This article provides an overview of current treatment options in first- and subsequent-line settings.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">healthbook TIMES. Oncology Hematology</subfield><subfield code="d">THE HEALTHBOOK COMPANY LTD., 2022</subfield><subfield code="g">9(2021), 3</subfield><subfield code="w">(DE-627)1786544288</subfield><subfield code="w">(DE-600)3106733-5</subfield><subfield code="x">26732106</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36000/hbT.OH.2021.09.046</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9e6d4a962e86486cae74a17616a331b6</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.36000/hbT.OH.2021.09.046</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2092</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2106</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield></datafield></record></collection>
|
score |
7.3985615 |